Clincosm LogoSign in Get a demo

DLBCL

Showing 1 - 25 of 48
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma

Recruiting
  • Lymphoma
  • +2 more
  • Shanghai, Shanghai, China
  • +2 more
May 9, 2023

B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

Recruiting
  • B-cell Lymphoma
  • +5 more
  • Louisville, Kentucky
    Norton Cancer Institute
Jan 24, 2023

CLL, SLL, Richter's Transformation Trial in United States (TG-1801, Ublituximab)

Recruiting
  • CLL
  • +9 more
  • TG-1801
  • Ublituximab
  • Fayetteville, Arkansas
  • +4 more
Jan 20, 2023

Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL Trial in Australia, Korea, Republic of, United States (IGM-2323)

Recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • Duarte, California
  • +23 more
Dec 28, 2022

Phase 1, NSCLC, SCLC Trial in United States (Oral MRT-2359)

Recruiting
  • NSCLC
  • +6 more
  • Oral MRT-2359
  • Scottsdale, Arizona
  • +7 more
Dec 20, 2022

Diffuse Large B Cell Lymphoma, DLBCL, Cancer Trial in Madison (Rituximab, Cyclophosphamide, Doxorubicin)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Dec 12, 2022

DLBCL, DLBCL Trial in Worldwide (Zilovertamab vedotin, Rituximab, Gemcitabine)

Recruiting
  • DLBCL
  • Diffuse Large B-Cell Lymphoma
  • Zilovertamab vedotin
  • +4 more
  • Whittier, California
  • +21 more
Nov 30, 2022

Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, DLBCL Trial in United States (KT-413)

Recruiting
  • Non Hodgkin Lymphoma
  • +3 more
  • Washington, District of Columbia
  • +5 more
Nov 29, 2022

Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) Trial in Augusta, Nashville, Houston

Recruiting
  • Mantle Cell Lymphoma
  • +9 more
  • L-Bcl-2 antisense oligonucleotide
  • Augusta, Georgia
  • +2 more
Nov 18, 2022

Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in United Kingdom, United States (AUTO3)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • AUTO3
  • Duarte, California
  • +10 more
Oct 19, 2022

Large B-cell Lymphoma, DLBCL Trial in New York (89Zr-DFO-REGN3767, PET/CT)

Recruiting
  • Large B-cell Lymphoma
  • DLBCL
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 3, 2022

DLBCL Trial in Hangzhou (Tafasitamab and Lenalidomide)

Recruiting
  • DLBCL
  • Tafasitamab and Lenalidomide
  • Hangzhou, Zhejiang, China
    The First Afflicated Hospital, College of Medicine, Zhejiang Uni
Sep 21, 2022

Mature B-Cell Tumor, Non Hodgkin Lymphoma, DLBCL Trial (SGR-1505)

Not yet recruiting
  • Mature B-Cell Neoplasm
  • +25 more
  • (no location specified)
Sep 14, 2022

AML Including AML de Novo and AML Secondary to MDS, DLBCL Trial (Birabresib Dose 20 mg)

Terminated
Has Results
  • AML Including AML de Novo and AML Secondary to MDS
  • DLBCL
  • Birabresib Dose 20 mg
  • (no location specified)
Aug 23, 2022

Advanced Solid Tumor, DLBCL Trial in United States (RNK05047)

Recruiting
  • Advanced Solid Tumor
  • DLBCL
  • Atlanta, Georgia
  • +3 more
Aug 23, 2022

DLBCL Trial in Qingdao (Selinexor combined with Prednisone, Etoposide, and Lenalidomide)

Not yet recruiting
  • DLBCL
  • Selinexor combined with Prednisone, Etoposide, and Lenalidomide
  • Qingdao, Shandong, China
    the affiliated hospital of Qingdao University
Aug 18, 2022

NHL, DLBCL, Non-hodgkin's Lymphoma Trial in United Kingdom, United States (AZD9150, Acalabrutinib, AZD6738)

Completed
  • NHL
  • +3 more
  • Los Angeles, California
  • +11 more
Aug 11, 2022

DLBCL Trial in China (Orelabrutinib and Gemox)

Not yet recruiting
  • DLBCL
  • Orelabrutinib and Gemox
  • Chongqing, Chongqing, China
  • +7 more
Jul 5, 2022

DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma Trial in Minneapolis (E7777)

Recruiting
  • DLBCL
  • +3 more
  • Minneapolis, Minnesota
    University of Minnesota, Masonic Cancer Center
Jul 1, 2022

DLBCL Trial in United States (MB-CART2019.1)

Recruiting
  • DLBCL
  • MB-CART2019.1
  • Gilbert, Arizona
  • +14 more
Jun 17, 2022

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

Recruiting
  • DLBCL
  • +8 more
  • Cardiac MRI
  • Bonn, NRW, Germany
    University Hospital Bonn
Jun 11, 2022

Advanced Solid Tumor, NSCLC, Melanoma Trial in United States (AB308, Zimberelimab)

Recruiting
  • Advanced Solid Tumor
  • +9 more
  • Phoenix, Arizona
  • +20 more
May 2, 2022

Primary Extranodal Lymphoma, DLBCL Trial (Camrelizumab)

Not yet recruiting
  • Primary Extranodal Lymphoma
  • DLBCL
  • (no location specified)
Apr 6, 2022

CLL/SLL, NHL, MCL Trial in United States (HMPL-760)

Recruiting
  • CLL/SLL
  • +8 more
  • Atlanta, Georgia
  • +3 more
Feb 24, 2022

Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma Trial in United States (CYT-0851, CYT-0851 in combination with gemcitabine,

Recruiting
  • Malignancy
  • +14 more
  • Scottsdale, Arizona
  • +17 more
Mar 7, 2022